Adjuvant chemotherapy for colon cancer

Area of Science:

• Oncology
• Gastroenterology
• Surgical Oncology

Background:

• Colorectal cancer is a leading global malignancy, particularly in Western countries.
• Surgical resection is the primary treatment, with adjuvant chemotherapy standard for stage III disease.
• 5-Fluorouracil/leucovorin is the current standard adjuvant chemotherapy for stage III colorectal cancer, administered for six months.

Purpose of the Study:

• To review the current standards of care for adjuvant therapy in colorectal cancer.
• To discuss the evolving role of chemotherapy in stage II and III disease.
• To highlight ongoing research into novel therapeutic agents and patient stratification.

Main Methods:

• Review of prospective randomized trials and clinical guidelines.
• Analysis of established and investigational adjuvant chemotherapy regimens.
• Exploration of molecular genetic factors for treatment selection in stage II colon cancer.

Main Results:

• Adjuvant chemotherapy is established for stage III colorectal cancer, with 5-fluorouracil/leucovorin for six months being the recommended regimen.
• Combining levamisole with 5-fluorouracil/leucovorin does not enhance efficacy.
• The benefit of adjuvant chemotherapy in stage II colon cancer remains uncertain, prompting research into molecular markers.

Conclusions:

• Standard adjuvant chemotherapy regimens and durations are defined for stage III colorectal cancer.
• Further research is needed to personalize adjuvant chemotherapy for stage II colorectal cancer using molecular markers.
• Investigational therapies, including non-fluorinated pyrimidine agents, are being evaluated in clinical trials.